Artivion, Inc. (AORT) · Insider trading
What Artivion's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$20.73M
8 insiders, 24% under a plan
Net, 12 months
−$20.73M
bought less sold
Latest filing
2026-09-11
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Mackin James PPresident & CEO | – | $13.59M | 16 | 2026-08-19 | 877,275 |
| Stanton Marshall S.SVP, Clinical & MD Affair | – | $5.89M | 27 | 2026-03-03 | 60,097 |
| Holloway Jean FSVP, General Counsel | – | $5.41M | 27 | 2026-08-12 | 184,118 |
| Davis John EChief Commercial Officer | – | $2.82M | 16 | 2026-03-03 | 230,794 |
| Green Andrew MSVP, Regulatory and Quality | – | $1.66M | 7 | 2026-09-10 | 40,160 |
| Horton AmyVP, Chief Accounting Officer | – | $1.42M | 15 | 2026-03-03 | 139,088 |
| Berry Lance AEVP, COO, CFO & Treasurer | – | $1.01M | 7 | 2026-08-14 | 210,112 |
| Hoff Elizabeth ADirector | – | $189,420 | 1 | 2025-11-18 | 27,189 |
| Semedo Anthony B.Director | $53,145 | $74,022 | 3 | 2025-05-23 | 39,384 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Green Andrew MSVP, Regulatory and Quality | Sale | 11,480 | 24.97 | $286,656 | 40,160 | Form 4 |
| 2026-09-03 | Green Andrew MSVP, Regulatory and Quality | Sale | 1,493 | 26.02 | $38,848 | 51,640 | Form 4 |
| 2026-09-02 | Green Andrew MSVP, Regulatory and Quality | Sale | 6,510 | 27.27 | $177,528 | 53,133 | Form 4 |
| 2026-08-19 | Mackin James PPresident & CEO | Sale | 70,000 | 28.96 | $2.03M | 877,275 | Form 4 |
| 2026-08-14 | Berry Lance AEVP, COO, CFO & Treasurer | Sale | 715 | 28.55 | $20,413 | 210,112 | Form 4 |
| 2026-08-14 | Green Andrew MSVP, Regulatory and Quality | Sale | 616 | 28.55 | $17,587 | 59,643 | Form 4 |
| 2026-08-12 | Holloway Jean FSVP, General Counsel | Sale | 977 | 28.49 | $27,835 | 184,118 | Form 4 |
| 2026-06-11 | Green Andrew MSVP, Regulatory and Quality | Saleplan | 14,001 | 20.71 | $289,961 | 60,259 | Form 4 |
| 2026-06-11 | Green Andrew MSVP, Regulatory and Quality | Saleplan | 30,000 | 20.69 | $620,700 | 60,259 | Form 4 |
| 2026-03-04 | Holloway Jean FSVP, General Counsel | Sale | 8,962 | 38.00 | $340,556 | 185,095 | Form 4 |
| 2026-03-03 | Mackin James PPresident & CEO | Sale | 17,887 | 37.78 | $675,771 | 947,275 | Form 4 |
| 2026-03-03 | Berry Lance AEVP, COO, CFO & Treasurer | Sale | 6,316 | 37.78 | $238,618 | 210,827 | Form 4 |
| 2026-03-03 | Davis John EChief Commercial Officer | Sale | 4,573 | 37.78 | $172,768 | 230,794 | Form 4 |
| 2026-03-03 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,149 | 37.78 | $81,189 | 60,097 | Form 4 |
| 2026-03-03 | Holloway Jean FSVP, General Counsel | Sale | 3,843 | 37.78 | $145,189 | 194,057 | Form 4 |
| 2026-03-03 | Horton AmyVP, Chief Accounting Officer | Sale | 901 | 37.78 | $34,040 | 139,088 | Form 4 |
| 2026-03-02 | Davis John EChief Commercial Officer | Sale | 2,784 | 38.02 | $105,848 | 206,522 | Form 4 |
| 2026-03-02 | Berry Lance AEVP, COO, CFO & Treasurer | Sale | 5,178 | 38.02 | $196,868 | 176,269 | Form 4 |
| 2026-03-02 | Holloway Jean FSVP, General Counsel | Sale | 2,183 | 38.02 | $82,998 | 170,105 | Form 4 |
| 2026-03-02 | Mackin James PPresident & CEO | Sale | 14,911 | 38.02 | $566,916 | 848,214 | Form 4 |
| 2026-03-02 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,513 | 38.02 | $57,524 | 40,408 | Form 4 |
| 2026-03-02 | Horton AmyVP, Chief Accounting Officer | Sale | 641 | 38.02 | $24,371 | 132,514 | Form 4 |
| 2026-02-24 | Davis John EChief Commercial Officer | Sale | 2,075 | 35.69 | $74,057 | 188,868 | Form 4 |
| 2026-02-24 | Berry Lance AEVP, COO, CFO & Treasurer | Sale | 4,485 | 35.69 | $160,070 | 143,965 | Form 4 |
| 2026-02-24 | Mackin James PPresident & CEO | Sale | 13,936 | 35.69 | $497,376 | 766,095 | Form 4 |
| 2026-02-24 | Holloway Jean FSVP, General Counsel | Sale | 1,668 | 35.69 | $59,531 | 152,203 | Form 4 |
| 2026-02-24 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,259 | 35.69 | $44,934 | 41,921 | Form 4 |
| 2026-02-24 | Horton AmyVP, Chief Accounting Officer | Sale | 830 | 35.69 | $29,623 | 127,497 | Form 4 |
| 2026-02-23 | Davis John EChief Commercial Officer | Sale | 3,773 | 37.59 | $141,827 | 190,943 | Form 4 |
| 2026-02-23 | Berry Lance AEVP, COO, CFO & Treasurer | Sale | 4,981 | 37.59 | $187,236 | 148,450 | Form 4 |
| 2026-02-23 | Mackin James PPresident & CEO | Sale | 20,962 | 37.59 | $787,962 | 780,031 | Form 4 |
| 2026-02-23 | Holloway Jean FSVP, General Counsel | Sale | 3,079 | 37.59 | $115,740 | 153,871 | Form 4 |
| 2026-02-23 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,423 | 37.59 | $91,081 | 43,180 | Form 4 |
| 2026-02-23 | Horton AmyVP, Chief Accounting Officer | Sale | 1,731 | 37.59 | $65,068 | 128,327 | Form 4 |
| 2025-12-15 | Davis John EChief Commercial Officer | Sale | 5,000 | 45.11 | $225,550 | 193,842 | Form 4 |
| 2025-12-08 | Horton AmyVP, Chief Accounting Officer | Sale | 4,572 | 44.42 | $203,088 | 130,058 | Form 4 |
| 2025-12-03 | Holloway Jean FSVP, General Counsel | Sale | 2,048 | 45.30 | $92,774 | 161,360 | Form 4 |
| 2025-12-03 | Holloway Jean FSVP, General Counsel | Sale | 5,267 | 45.30 | $238,595 | 156,093 | Form 4 |
| 2025-12-03 | Mackin James PPresident & CEO | Saleplan | 30,921 | 45.46 | $1.41M | 800,993 | Form 4 |
| 2025-12-02 | Mackin James PPresident & CEO | Saleplan | 30,921 | 45.56 | $1.41M | 800,993 | Form 4 |
79 more
| 2025-11-21 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 14,586 | 44.92 | $655,203 | 50,468 | Form 4 |
| 2025-11-21 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 5,715 | 45.35 | $259,175 | 44,753 | Form 4 |
| 2025-11-21 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 18,705 | 44.91 | $840,042 | 53,123 | Form 4 |
| 2025-11-21 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 8,370 | 45.35 | $379,580 | 44,753 | Form 4 |
| 2025-11-20 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 11,888 | 44.14 | $524,736 | 44,753 | Form 4 |
| 2025-11-20 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,033 | 44.32 | $90,103 | 44,753 | Form 4 |
| 2025-11-20 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,355 | 44.28 | $59,999 | 44,753 | Form 4 |
| 2025-11-18 | Hoff Elizabeth ADirector | Sale | 4,200 | 45.10 | $189,420 | 27,189 | Form 4 |
| 2025-11-17 | Horton AmyVP, Chief Accounting Officer | Sale | 6,000 | 45.73 | $274,380 | 135,380 | Form 4 |
| 2025-11-17 | Davis John EChief Commercial Officer | Saleplan | 6,394 | 45.17 | $288,817 | 198,842 | Form 4 |
| 2025-11-17 | Holloway Jean FSVP, General Counsel | Saleplan | 6,394 | 45.17 | $288,817 | 163,408 | Form 4 |
| 2025-11-14 | Davis John EChief Commercial Officer | Saleplan | 6,393 | 44.67 | $285,575 | 198,842 | Form 4 |
| 2025-11-14 | Holloway Jean FSVP, General Counsel | Saleplan | 6,393 | 45.00 | $287,685 | 163,408 | Form 4 |
| 2025-11-13 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 4,993 | 45.86 | $228,979 | 56,641 | Form 4 |
| 2025-11-13 | Holloway Jean FSVP, General Counsel | Sale | 5,761 | 45.86 | $264,199 | 163,408 | Form 4 |
| 2025-11-13 | Mackin James PPresident & CEO | Sale | 34,210 | 45.86 | $1.57M | 800,993 | Form 4 |
| 2025-11-13 | Davis John EChief Commercial Officer | Sale | 6,563 | 45.86 | $300,979 | 198,842 | Form 4 |
| 2025-11-13 | Horton AmyVP, Chief Accounting Officer | Sale | 3,482 | 45.86 | $159,685 | 141,380 | Form 4 |
| 2025-11-11 | Holloway Jean FSVP, General Counsel | Sale | 10,000 | 46.18 | $461,800 | 169,169 | Form 4 |
| 2025-11-10 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,566 | 44.62 | $114,495 | 61,634 | Form 4 |
| 2025-11-10 | Horton AmyVP, Chief Accounting Officer | Sale | 1,789 | 44.62 | $79,825 | 144,862 | Form 4 |
| 2025-11-10 | Davis John EChief Commercial Officer | Sale | 3,373 | 44.62 | $150,503 | 205,405 | Form 4 |
| 2025-11-10 | Mackin James PPresident & CEO | Sale | 17,580 | 44.62 | $784,420 | 835,203 | Form 4 |
| 2025-11-10 | Holloway Jean FSVP, General Counsel | Sale | 2,960 | 44.62 | $132,075 | 169,169 | Form 4 |
| 2025-08-27 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 18,200 | 44.02 | $801,164 | 64,200 | Form 4 |
| 2025-08-25 | Holloway Jean FSVP, General Counsel | Sale | 10,000 | 44.37 | $443,700 | 172,129 | Form 4 |
| 2025-08-15 | Mackin James PPresident & CEO | Sale | 12,500 | 42.32 | $529,000 | 852,783 | Form 4 |
| 2025-08-12 | Holloway Jean FSVP, General Counsel | Sale | 16,975 | 43.01 | $730,095 | 178,510 | Form 4 |
| 2025-08-12 | Holloway Jean FSVP, General Counsel | Sale | 6,381 | 43.02 | $274,511 | 172,129 | Form 4 |
| 2025-08-12 | Davis John EChief Commercial Officer | Sale | 10,802 | 43.67 | $471,723 | 208,778 | Form 4 |
| 2025-08-08 | Horton AmyVP, Chief Accounting Officer | Saleplan | 7,992 | 38.49 | $307,612 | 146,651 | Form 4 |
| 2025-06-17 | Stanton Marshall S.SVP, Clinical & MD Affair | Saleplan | 13,764 | 29.50 | $406,038 | 65,436 | Form 4 |
| 2025-06-17 | Stanton Marshall S.SVP, Clinical & MD Affair | Saleplan | 1,236 | 29.50 | $36,462 | 64,200 | Form 4 |
| 2025-06-13 | Stanton Marshall S.SVP, Clinical & MD Affair | Saleplan | 8,747 | 28.46 | $248,940 | 96,585 | Form 4 |
| 2025-06-13 | Stanton Marshall S.SVP, Clinical & MD Affair | Saleplan | 1,253 | 28.47 | $35,673 | 95,332 | Form 4 |
| 2025-06-13 | Stanton Marshall S.SVP, Clinical & MD Affair | Saleplan | 14,306 | 28.42 | $406,577 | 81,026 | Form 4 |
| 2025-06-13 | Stanton Marshall S.SVP, Clinical & MD Affair | Saleplan | 1,826 | 28.43 | $51,913 | 79,200 | Form 4 |
| 2025-05-27 | Holloway Jean FSVP, General Counsel | Sale | 8,748 | 29.00 | $253,692 | 178,510 | Form 4 |
| 2025-05-23 | Semedo Anthony B.Director | Sale | 2,600 | 28.47 | $74,022 | 39,384 | Form 4/A |
| 2025-05-21 | Holloway Jean FSVP, General Counsel | Sale | 9,926 | 29.00 | $287,854 | 187,258 | Form 4 |
| 2025-05-09 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 5,737 | 29.13 | $167,119 | 110,143 | Form 4 |
| 2025-05-09 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 4,811 | 29.13 | $140,144 | 105,332 | Form 4 |
| 2025-03-11 | Davis John EChief Commercial Officer | Saleplan | 15,100 | 23.61 | $356,511 | 208,778 | Form 4 |
| 2025-03-11 | Holloway Jean FSVP, General Counsel | Saleplan | 18,020 | 23.61 | $425,452 | 197,184 | Form 4 |
| 2025-03-06 | Holloway Jean FSVP, General Counsel | Sale | 2,124 | 24.80 | $52,675 | 196,112 | Form 4 |
| 2025-03-06 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,603 | 24.80 | $39,754 | 115,880 | Form 4 |
| 2025-03-06 | Davis John EChief Commercial Officer | Sale | 2,618 | 24.80 | $64,926 | 207,968 | Form 4 |
| 2025-03-06 | Berry Lance AExecutive VP, CFO | Sale | 4,909 | 24.80 | $121,743 | 153,431 | Form 4 |
| 2025-03-06 | Horton AmyVP, Chief Accounting Officer | Sale | 1,048 | 24.80 | $25,990 | 146,651 | Form 4 |
| 2025-03-06 | Mackin James PPresident & CEO | Saleplan | 17,739 | 24.80 | $439,927 | 860,368 | Form 4 |
| 2025-03-06 | Mackin James PPresident & CEO | Saleplan | 70,700 | 24.76 | $1.75M | 865,283 | Form 4 |
| 2025-03-05 | Holloway Jean FSVP, General Counsel | Sale | 472 | 25.29 | $11,937 | 172,743 | Form 4 |
| 2025-03-05 | Semedo Anthony B.Director | Buy | 1,500 | 25.33 | $37,995 | 35,659 | Form 4 |
| 2025-03-05 | Semedo Anthony B.Director | Buyindirect | 600 | 25.25 | $15,150 | 600 | Form 4 |
| 2025-02-24 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 2,299 | 27.31 | $62,786 | 82,233 | Form 4 |
| 2025-02-24 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 470 | 27.31 | $12,836 | 81,763 | Form 4 |
| 2025-02-24 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 672 | 27.31 | $18,352 | 81,091 | Form 4 |
| 2025-02-24 | Stanton Marshall S.SVP, Clinical & MD Affair | Sale | 1,246 | 27.31 | $34,028 | 79,845 | Form 4 |
| 2025-02-24 | Berry Lance AExecutive VP, CFO | Sale | 3,259 | 27.31 | $89,003 | 75,805 | Form 4 |
| 2025-02-24 | Davis John EChief Commercial Officer | Sale | 2,846 | 27.31 | $77,724 | 164,242 | Form 4 |
| 2025-02-24 | Davis John EChief Commercial Officer | Sale | 591 | 27.31 | $16,140 | 163,651 | Form 4 |
| 2025-02-24 | Davis John EChief Commercial Officer | Sale | 985 | 27.31 | $26,900 | 162,666 | Form 4 |
| 2025-02-24 | Davis John EChief Commercial Officer | Sale | 2,035 | 27.31 | $55,576 | 160,631 | Form 4 |
| 2025-02-24 | Holloway Jean FSVP, General Counsel | Sale | 2,385 | 27.31 | $65,134 | 152,749 | Form 4 |
| 2025-02-24 | Holloway Jean FSVP, General Counsel | Sale | 490 | 27.31 | $13,382 | 152,259 | Form 4 |
| 2025-02-24 | Holloway Jean FSVP, General Counsel | Sale | 810 | 27.31 | $22,121 | 151,449 | Form 4 |
| 2025-02-24 | Holloway Jean FSVP, General Counsel | Sale | 1,650 | 27.31 | $45,062 | 149,799 | Form 4 |
| 2025-02-24 | Mackin James PPresident & CEO | Sale | 16,664 | 27.31 | $455,094 | 689,374 | Form 4 |
| 2025-02-24 | Mackin James PPresident & CEO | Sale | 13,784 | 27.31 | $376,441 | 675,590 | Form 4 |
| 2025-02-24 | Mackin James PPresident & CEO | Sale | 6,812 | 27.31 | $186,036 | 668,778 | Form 4 |
| 2025-02-24 | Mackin James PPresident & CEO | Sale | 4,896 | 27.31 | $133,710 | 663,882 | Form 4 |
| 2025-02-24 | Horton AmyVP, Chief Accounting Officer | Sale | 1,706 | 27.31 | $46,591 | 132,758 | Form 4 |
| 2025-02-24 | Horton AmyVP, Chief Accounting Officer | Sale | 814 | 27.31 | $22,230 | 131,944 | Form 4 |
| 2025-02-24 | Horton AmyVP, Chief Accounting Officer | Sale | 318 | 27.31 | $8,685 | 131,626 | Form 4 |
| 2025-02-24 | Horton AmyVP, Chief Accounting Officer | Sale | 485 | 27.31 | $13,245 | 131,141 | Form 4 |
| 2024-12-11 | Holloway Jean FSVP, General Counsel | Sale | 4,035 | 30.25 | $122,059 | 157,897 | Form 4 |
| 2024-12-11 | Holloway Jean FSVP, General Counsel | Sale | 4,035 | 30.00 | $121,050 | 153,862 | Form 4 |
| 2024-12-06 | Horton AmyVP, Chief Accounting Officer | Sale | 4,425 | 29.05 | $128,546 | 135,564 | Form 4/A |
| 2024-12-04 | Green Andrew MVP Regulatory | Saleplan | 7,618 | 30.00 | $228,540 | 33,503 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
47 × grant or award21 × option exercise2 × other2 × gift
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Green Andrew MSVP, Regulatory and Quality | Option exercise M | +14,001 | 18.44 | 74,260 | Form 4 |
| 2026-06-11 | Green Andrew MSVP, Regulatory and Quality | Option exercise M | +30,000 | 11.03 | 90,259 | Form 4 |
| 2026-06-02 | Semedo Anthony B.Director | Other J | −6,325 | – | 40,635 | Form 4 |
| 2026-06-02 | Semedo Anthony B.Director | Other J | +6,325 | – | 6,325 | Form 4 |
| 2026-05-18 | Ackerman Thomas FDirector | Grant or award A | +7,576 | – | 157,472 | Form 4 |
| 2026-05-18 | Bevevino Daniel JDirector | Grant or award A | +7,576 | – | 157,637 | Form 4 |
| 2026-05-18 | Bullock JamesDirector | Grant or award A | +7,576 | – | 76,223 | Form 4 |
| 2026-05-18 | Burbank Jeffrey HDirector | Grant or award A | +7,576 | – | 61,372 | Form 4 |
| 2026-05-18 | Hoff Elizabeth ADirector | Grant or award A | +7,576 | – | 34,765 | Form 4 |
| 2026-05-18 | Salveson Jon WDirector | Grant or award A | +7,576 | – | 137,416 | Form 4 |
| 2026-05-18 | Semedo Anthony B.Director | Grant or award A | +7,576 | – | 46,960 | Form 4 |
| 2026-05-18 | Borgstrom Marna PDirector | Grant or award A | +7,576 | – | 56,664 | Form 4/A |
| 2026-05-14 | Borgstrom Marna PDirector | Grant or award A | +7,850 | – | 56,938 | Form 4 |
| 2026-03-02 | Mackin James PPresident & CEO | Grant or award A | +116,948 | – | 965,162 | Form 4 |
| 2026-03-02 | Berry Lance AEVP, COO, CFO & Treasurer | Grant or award A | +40,874 | – | 217,143 | Form 4 |
| 2026-03-02 | Davis John EChief Commercial Officer | Grant or award A | +28,845 | – | 235,367 | Form 4 |
| 2026-03-02 | Stanton Marshall S.SVP, Clinical & MD Affair | Grant or award A | +21,838 | – | 62,246 | Form 4 |
| 2026-03-02 | Holloway Jean FSVP, General Counsel | Grant or award A | +27,795 | – | 197,900 | Form 4 |
| 2026-03-02 | Horton AmyVP, Chief Accounting Officer | Grant or award A | +7,475 | – | 139,989 | Form 4 |
| 2026-02-24 | Davis John EChief Commercial Officer | Grant or award A | +20,438 | – | 209,306 | Form 4 |
| 2026-02-24 | Berry Lance AEVP, COO, CFO & Treasurer | Grant or award A | +37,482 | – | 181,447 | Form 4 |
| 2026-02-24 | Mackin James PPresident & CEO | Grant or award A | +97,030 | – | 863,125 | Form 4 |
| 2026-02-24 | Holloway Jean FSVP, General Counsel | Grant or award A | +20,085 | – | 172,288 | Form 4 |
| 2026-02-24 | Horton AmyVP, Chief Accounting Officer | Grant or award A | +5,658 | – | 133,155 | Form 4 |
| 2025-12-31 | Holloway Jean FSVP, General Counsel | Grant or award A | +228 | 26.14 | 156,950 | Form 5 |
| 2025-12-31 | Stanton Marshall S.SVP, Clinical & MD Affair | Grant or award A | +316 | 26.14 | 45,603 | Form 5 |
| 2025-12-03 | Mackin James PPresident & CEO | Option exercise M | +30,921 | 29.62 | 831,914 | Form 4 |
| 2025-12-02 | Mackin James PPresident & CEO | Option exercise M | +30,921 | 29.62 | 831,914 | Form 4 |
| 2025-12-01 | Horton AmyVP, Chief Accounting Officer | Gift G | −750 | – | 134,630 | Form 4 |
| 2025-11-21 | Stanton Marshall S.SVP, Clinical & MD Affair | Option exercise M | +20,301 | 18.44 | 65,054 | Form 4 |
| 2025-11-21 | Stanton Marshall S.SVP, Clinical & MD Affair | Option exercise M | +27,075 | 11.03 | 71,828 | Form 4 |
| 2025-11-20 | Stanton Marshall S.SVP, Clinical & MD Affair | Option exercise M | +2,033 | 18.44 | 46,786 | Form 4 |
| 2025-11-20 | Stanton Marshall S.SVP, Clinical & MD Affair | Option exercise M | +1,355 | 11.03 | 46,108 | Form 4 |
| 2025-11-17 | Davis John EChief Commercial Officer | Option exercise M | +6,394 | 29.62 | 205,236 | Form 4 |
| 2025-11-17 | Holloway Jean FSVP, General Counsel | Option exercise M | +6,394 | 29.62 | 169,802 | Form 4 |
| 2025-11-14 | Davis John EChief Commercial Officer | Option exercise M | +6,393 | 29.62 | 205,235 | Form 4 |
| 2025-11-14 | Holloway Jean FSVP, General Counsel | Option exercise M | +6,393 | 29.62 | 169,801 | Form 4 |
| 2025-11-11 | Holloway Jean FSVP, General Counsel | Option exercise M | +10,000 | 11.03 | 179,169 | Form 4 |
| 2025-08-27 | Stanton Marshall S.SVP, Clinical & MD Affair | Option exercise M | +18,200 | 11.03 | 82,400 | Form 4 |
| 2025-08-25 | Holloway Jean FSVP, General Counsel | Option exercise M | +10,000 | 11.03 | 182,129 | Form 4 |
| 2025-08-12 | Holloway Jean FSVP, General Counsel | Option exercise M | +16,975 | 26.24 | 195,485 | Form 4 |
| 2025-08-12 | Davis John EChief Commercial Officer | Option exercise M | +10,802 | 26.24 | 219,580 | Form 4 |
| 2025-08-08 | Horton AmyVP, Chief Accounting Officer | Option exercise M | +7,992 | 29.62 | 154,643 | Form 4 |
| 2025-06-30 | Holloway Jean FSVP, General Counsel | Grant or award A | +629 | 24.30 | 156,722 | Form 5 |
| 2025-06-30 | Davis John EChief Commercial Officer | Grant or award A | +874 | 24.30 | 194,716 | Form 5 |
| 2025-06-30 | Stanton Marshall S.SVP, Clinical & MD Affair | Grant or award A | +534 | 24.30 | 45,287 | Form 5 |
| 2025-05-22 | Bullock JamesDirector | Grant or award A | +6,325 | – | 68,647 | Form 4 |
| 2025-05-22 | Burbank Jeffrey HDirector | Grant or award A | +6,325 | – | 53,796 | Form 4 |
| 2025-05-22 | Hoff Elizabeth ADirector | Grant or award A | +6,325 | – | 31,389 | Form 4 |
| 2025-05-22 | Salveson Jon WDirector | Grant or award A | +6,325 | – | 129,840 | Form 4 |
| 2025-05-22 | Ackerman Thomas FDirector | Grant or award A | +6,325 | – | 149,896 | Form 4 |
| 2025-05-22 | Bevevino Daniel JDirector | Grant or award A | +6,325 | – | 150,061 | Form 4 |
| 2025-05-22 | Borgstrom Marna PDirector | Grant or award A | +6,325 | – | 49,088 | Form 4 |
| 2025-05-22 | Semedo Anthony B.Director | Grant or award A | +6,325 | – | 41,984 | Form 4 |
| 2025-03-11 | Davis John EChief Commercial Officer | Option exercise M | +15,910 | 21.55 | 223,878 | Form 4 |
| 2025-03-11 | Holloway Jean FSVP, General Counsel | Option exercise M | +19,092 | 21.55 | 215,204 | Form 4 |
| 2025-03-06 | Holloway Jean FSVP, General Counsel | Grant or award A | +25,493 | – | 198,236 | Form 4 |
| 2025-03-06 | Stanton Marshall S.SVP, Clinical & MD Affair | Grant or award A | +19,240 | – | 117,483 | Form 4 |
| 2025-03-06 | Davis John EChief Commercial Officer | Grant or award A | +25,654 | – | 210,586 | Form 4 |
| 2025-03-06 | Berry Lance AExecutive VP, CFO | Grant or award A | +48,100 | – | 158,340 | Form 4 |
| 2025-03-06 | Horton AmyVP, Chief Accounting Officer | Grant or award A | +10,261 | – | 147,699 | Form 4 |
| 2025-03-06 | Mackin James PPresident & CEO | Grant or award A | +115,701 | – | 878,107 | Form 4 |
| 2025-03-06 | Mackin James PPresident & CEO | Option exercise M | +75,615 | 21.55 | 935,983 | Form 4 |
| 2025-02-28 | Berry Lance AExecutive VP, CFO | Grant or award A | +34,435 | – | 110,240 | Form 4 |
| 2025-02-28 | Davis John EChief Commercial Officer | Grant or award A | +24,301 | – | 184,932 | Form 4 |
| 2025-02-28 | Holloway Jean FSVP, General Counsel | Grant or award A | +23,416 | – | 173,215 | Form 4 |
| 2025-02-28 | Horton AmyVP, Chief Accounting Officer | Grant or award A | +6,297 | – | 137,438 | Form 4 |
| 2025-02-28 | Mackin James PPresident & CEO | Grant or award A | +98,524 | – | 762,406 | Form 4 |
| 2025-02-28 | Stanton Marshall S.SVP, Clinical & MD Affair | Grant or award A | +18,398 | – | 98,243 | Form 4 |
| 2024-12-31 | Holloway Jean FSVP, General Counsel | Grant or award A | +295 | 21.63 | 155,134 | Form 5 |
| 2024-12-31 | Stanton Marshall S.SVP, Clinical & MD Affair | Grant or award A | +381 | 21.63 | 84,532 | Form 5 |
| 2024-12-12 | Horton AmyVP, Chief Accounting Officer | Gift G | −1,100 | – | 134,464 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.